A

    Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $17.47
    -0.07 (-0.40%)

    Market Cap: $6.11B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    78%(31/40)
    Avg Surprise
    +17.86%
    Streak
    6 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.23
    Range$0.22 - $0.23
    4 analysts
    EPS RevisionsNo revisions (7d)
    0
    3
    30d
    EPS Estimate Drift
    90d ago$0.28+23.5%
    60d ago$0.25+10.2%
    30d ago$0.25+10.2%
    7d ago$0.24+4.7%
    Current$0.23
    Revenue Consensus
    $805M
    Range$792M - $816M
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.38
    Range$0.31 - $0.41
    4 analysts
    Revenue Consensus
    $856M
    Range$821M - $885M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.38---
    Sep 26EST
    		-$0.23---
    Jun 26
    Reported Jul 30
    		$0.27$0.24+12.50%Beat+8.0%
    Mar 26
    Reported May 7
    		$0.27$0.19+38.96%Beat+28.6%
    Dec 25
    Reported Feb 27
    		$0.21$0.18+16.67%Beat+75.0%
    Sep 25
    Reported Oct 30
    		$0.17$0.14+21.43%Beat+6.3%
    Jun 25
    Reported Aug 5
    		$0.25$0.17+47.06%Beat+56.3%
    Mar 25
    Reported May 2
    		$0.21$0.15+40.00%Beat+50.0%
    Dec 24
    Reported Feb 28
    		$0.12$0.15-20.00%Miss-14.3%
    Sep 24
    Reported Nov 8
    		$0.16$0.14+14.29%Beat-15.8%
    Jun 24
    Reported Aug 9
    		$0.16$0.14+14.29%Beat-15.8%
    Mar 24
    Reported May 3
    		$0.14$0.09+55.56%Beat+16.7%
    Dec 23
    Reported Mar 1
    		$0.14$0.09+55.56%Beat-39.1%
    Sep 23
    Reported Nov 7
    		$0.19$0.13+46.15%Beat+35.7%
    Jun 23
    Reported Aug 4
    		$0.19$0.10+90.00%Beat+0.0%
    Mar 23
    Reported May 5
    		$0.12$0.10+20.00%Beat+0.0%
    Dec 22
    Reported Mar 2
    		$0.23$0.21+9.52%Beat+27.8%
    Sep 22
    Reported Nov 4
    		$0.14$0.18-22.22%Miss-33.3%
    Jun 22
    Reported Aug 5
    		$0.19$0.19+0.00%Beat-24.0%
    Mar 22
    Reported May 4
    		$0.12$0.13-7.69%Miss-40.0%
    Dec 21
    Reported Mar 2
    		$0.18$0.20-10.00%Miss+28.6%
    Sep 21
    Reported Nov 3
    		$0.21$0.20+5.00%Beat+31.2%
    Jun 21
    Reported Aug 9
    		$0.25$0.18+38.89%Beat+92.3%
    Mar 21
    Reported May 7
    		$0.20$0.18+11.11%Beat+0.0%
    Dec 20
    Reported Feb 26
    		$0.14$0.13+7.69%Beat+75.0%
    Sep 20
    Reported Nov 6
    		$0.16$0.12+33.33%Beat+300.0%
    Jun 20
    Reported Aug 6
    		$0.13$0.10+30.00%Beat+44.4%
    Mar 20
    Reported May 11
    		$0.20$0.09+122.22%Beat+42.9%
    Dec 19
    Reported Feb 26
    		$0.08$0.05+60.00%Beat-75.8%
    Sep 19
    Reported Nov 6
    		$0.04N/A-69.23%Miss-85.7%
    Jun 19
    Reported Aug 5
    		$0.09$0.12-25.00%Miss-62.5%
    Mar 19
    Reported May 9
    		$0.14$0.18-22.22%Miss+0.0%
    Dec 18
    Reported Feb 28
    		$0.33$0.27+22.22%Beat+200.0%
    Sep 18
    Reported Nov 7
    		$0.28$0.27+3.70%Beat+21.7%
    Jun 18
    Reported Aug 9
    		$0.24$0.22+9.09%Beat+33.3%
    Mar 18
    Reported May 7
    		$0.14$0.10+40.00%Beat+27.3%
    Dec 17
    Reported Mar 1
    		$0.11$0.11+0.00%Beat-31.3%
    Sep 17
    Reported Nov 9
    		$0.23$0.20+15.00%Beat-37.8%
    Jun 17
    Reported Aug 9
    		$0.18$0.14+28.57%Beat-
    Mar 17
    Reported May 10
    		$0.11$0.13-15.38%Miss-
    Dec 16
    Reported Mar 1
    		$0.16$0.16+0.00%Beat-
    Sep 16
    Reported Nov 9
    		$0.37$0.38-2.63%Miss-

    Key Metrics

    Valuation
    P/E Ratio18.99EV/EBITDA14.35x
    Price/FCF67.10xFCF Yield1.49%
    Profitability
    Profit Margin5.05%Operating Margin18.30%
    ROE61.30%ROIC17.15%
    Financial Health
    Debt/Equity80.86xInterest Coverage13.12x
    Current Ratio2.20xQuick Ratio1.44x
    Trading Statistics
    Beta1.25Avg Volume1.69M
    52-Week High$19.2652-Week Low$9.32

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$17.88
    SMA 20$17.92
    SMA 50$17.69
    SMA 200$14.25
    EMA 10$17.81
    EMA 20$17.86
    EMA 50$17.28
    EMA 200$14.45

    MACD

    Line: 0.03Signal: 0.13Hist: -0.10

    ADX

    ADX: 18.8+DI: 15.0-DI: 26.6

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down48.0
    PSAR$17.10

    Bollinger Bands

    Upper Band$18.67
    Lower Band$17.18
    %B Position831%(Upper)
    Band Width0.20

    RSI (14-Day)

    Neutral
    45.1

    Momentum Oscillators

    Stoch %K45.4
    Stoch %D53.2
    Williams %R-64.8
    ROC (10d)-5.2%
    Momentum-0.95
    CCI (20d)-118.9
    MFI (14d)50.8

    Volatility Measures

    ATR (14d)$0.57(3.2%)
    StdDev (20d)0.37
    Hist Vol33.0%(Moderate)

    Volume Flow

    VWAP$17.42
    OBV85.3M
    AD Line-2.7M
    CMF (20d)-0.061

    Volume Metrics

    Avg Vol (20d)1.7M
    Vol Ratio1.0x
    VWMA (20d)$17.90

    Pivot Points

    R3$18.57
    R2$18.33
    R1$17.94
    Pivot Point$17.70
    S1$17.31
    S2$17.07
    S3$16.68

    Advanced Oscillators

    TSI1.36
    Ultimate Osc55.2
    KST0.78

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$796.20M$722.52M$814.32M$784.51M$724.51M$695.42M$730.52M$702.47M$701.78M$659.19M$616.98M$620.04M
    Cost of Revenue$461.69M$402.41M$517.13M$510.54M$438.25M$439.53M$467.64M$432.91M$451.83M$421.13M$427.15M$387.51M
    Gross Profit$334.51M$320.11M$297.19M$273.97M$286.25M$255.89M$262.87M$269.56M$249.95M$238.06M$189.83M$232.53M
    Operating Expenses$204.74M$178.34M$185.16M$203.63M$174.88M$155.54M$187.08M$180.75M$154.48M$248.81M$175.63M$156.88M
    R&D$41.10M$39.92M$36.23M$65.79M$49.98M$41.81M$56.12M$63.06M$37.10M$40.28M$49.91M$41.38M
    SG&A$148.72M$138.86M$146.46M$137.81M$124.27M$118.29M$128.69M$118.69M$116.46M$112.59M$109.00M$113.01M
    Operating Income$129.77M$141.77M$112.03M$70.34M$111.37M$100.35M$75.79M$88.81M$95.47M$-10,746,000$14.19M$75.65M
    Interest Income$-55,043,000$-53,361,000$-56,237,000$-62,814,000$-65,101,000$-56,939,000$-61,662,000$-65,511,000$-65,719,000$-65,703,000$-59,548,000$-50,909,000
    Interest Expense$0$3.51M$56.80M$31.36M$0$0$91.11M$0$75.06M$64.78M$97.65M$52.69M
    Income Before Tax$70.99M$80.18M$55.23M$-5,223,000$51.71M$37.49M$-15,319,000$15.42M$20.41M$-75,522,000$-83,461,000$22.96M
    Income Tax Expense$1.38M$2.18M$5.66M$-23,355,000$16.10M$12.87M$5.42M$3.67M$3.62M$6.16M$9.86M$-2,076,000
    Net Income$69.61M$78.00M$49.57M$18.13M$35.61M$24.62M$-20,742,000$11.76M$16.79M$-81,678,000$-93,344,000$25.03M
    EBITDA$177.90M$184.13M$164.41M$148.06M$183.80M$161.40M$119.29M$147.92M$149.15M$52.51M$78.49M$133.43M
    EBIT$126.03M$137.05M$111.47M$88.96M$116.81M$94.42M$46.34M$80.93M$86.12M$-9,819,000$16.89M$73.87M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about AMRX

    News

    Amneal (NASDAQ: AMRX) EVP gifts 152K shares to family trust

    Amneal Pharmaceuticals, Inc. (AMRX) Executive Vice President Andrew S. Boyer gifted 152,426 shares of Class A Common Stock to a family trust on August 21, 2026. This bona fide gift, with a transaction price of $0.00 per share, means Boyer no longer serves as trustee for these shares. Following the transaction, Boyer's direct holdings amount to 273,646 shares of Class A Common Stock.

    Stock Titan•8/25/26•
    Neutral

    Amneal Pharmaceuticals (AMRX) Stock Looks Fairly Valued But Earnings Still Look Rich

    Amneal Pharmaceuticals (AMRX) has seen a significant 344% gain over the past three years, leading to a valuation that appears less obviously cheap. The stock trades at a P/E ratio of 36.3x, more than double the industry average, yet its model-based fair P/E is close at 34.7x. The article highlights a split among investors, with some optimistic about biosimilar expansion and others concerned about execution risks and capital intensity.

    Sahm•8/22/26•
    Neutral

    Amneal (AMRX) Stock Looks Fairly Valued Following Raised 2026 Guidance

    Amneal Pharmaceuticals (AMRX) has seen a 345.7% return over the past three years, leading to a valuation that appears fairly priced rather than an obvious bargain. While strong Q2 2026 results and raised full-year guidance support the current valuation, the stock trades at a P/E ratio of 37.1x, above the industry average, suggesting that much of the good news may already be factored in. The stock's future performance hinges on its ability to sustain strong earnings and margin growth to justify its premium valuation.

    Sahm•8/19/26•
    Neutral

    Amneal Pharmaceuticals (AMRX) director sells 50,000 shares, gifts 10,000 to charity

    Amneal Pharmaceuticals director John Kiely reported selling 50,000 shares of Class A Common Stock at a weighted average price of $17.64 per share on August 13, 2026. Additionally, he made a charitable donation of 10,000 shares of Class A Common Stock to a donor-advised fund on the same date. Following these transactions, Kiely directly holds 200,252 shares of Class A Common Stock.

    Stock Titan•8/14/26•
    Somewhat-Bearish

    Amneal Pharmaceuticals Director John Kiely Sells 50,000 Shares and Donates 10,000 Shares on August 13, 2026

    John Kiely, a director at Amneal Pharmaceuticals (NASDAQ: AMRX), sold 50,000 shares of Class A Common Stock at an average price of $17.64 and donated 10,000 shares to a donor-advised fund on August 13, 2026. After these transactions, Kiely's direct ownership in the company stands at 200,252 shares. The details were revealed in a Form 4 filing on August 14, 2026.

    Kalkine Media•8/14/26•
    Neutral

    Frequently Asked Questions About AMRX

    Does AMRX pay dividends?
    Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) does not currently pay a regular dividend.
    What is AMRX's P/E ratio?
    Amneal Pharmaceuticals, Inc. Class A Common Stock has a price-to-earnings (P/E) ratio of 18.99.
    What is AMRX's market cap?
    Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) has a market capitalization of $6.11B with a current stock price of $17.47.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In